8/13/2023 0 Comments Vaccine production usa![]() Additionally, the company is also collaborating with the US-based Translate Bio to develop an mRNA-based coronavirus vaccine. Sanofi is joining forces with GSK to create an adjuvant recombinant protein-based vaccine for COVID-19. These also accounted for a large portion of the company’s USD 6.3 billion vaccine sales in 2019. The company has earned its reputation as a pharmaceutical bigwig due to its role as a leading supplier of vaccines against DTaP, Polio, Haemophilus Influenzae Type B, and Influenza. Sanofi is a major player in the market, occupying the fourth position with a 13% share in the global market. Pfizer also boasts late-stage vaccine candidates for Respiratory Syncytial Virus, Meningococcal, Pneumococcal, and Clostridioides difficile. The first doses were administered in the UK on December 8, 2020. The company’s mRNA-based COVID-19 vaccine, which is developed in collaboration with BioNTech SE, was the first to get approved by the UK’s Medical and Pharmaceutical Regulatory Agency (MHRA). This pharmaceutical behemoth holds a 14% share in the global vaccines market, with the company bringing USD 6.5 billion in sales revenues in 2019. Moreover, the company also features two late-stage vaccines against cytomegalovirus and pneumococcal. It also acquired Themis, a research-based pharmaceutical company, to formulate another coronavirus vaccine using a measles virus vector platform. The clinical trials for the vaccine were supposed to commence in the latter half of 2020. Merck has teamed up with the International AIDS Vaccine Initiative to develop a vaccine for COVID-19 that leverages the recombinant Vesicular Stomatitis Virus (rVSV) platform. The company’s vaccines against rotavirus, varicella, pneumococcal, and HPV dominated its sales in 2019, with the company selling 190 million vaccine doses globally. is the second-largest player in the market, generating revenues worth USD 8.4 billion in 2019. (The US)Īccounting for an 18% share, Merck & Co. However, the coronavirus pandemic led to an 8% decline in its vaccine sales in the first nine months of 2020. It also has 15 pipeline candidates for Malaria, COPD, Shigella Diarrhea, and Respiratory Syncytial Virus. GSK is partnering with Sanofi to develop a protein-based vaccine candidate, which completed its Phase 2 trials in September and will enter Phase 3 trials towards 2020. The company is known for its vaccines against meningococcal disease, polio, hepatitis B, DTaP (Diphtheria, Tetanus, and Pertussis), and selling 701 million doses globally in 2019. GlaxoSmithKline (GSK) is the largest player in the global vaccines market, dominating the market with a 20% revenue share and generating USD 9.1 billion in sales in 2019. Top 5 Players in the Vaccines Market: GlaxoSmithKline (The UK) Fluzone Influenza by Sanofi that generated USD 2.1 billion in 2019Īccording to Fortune Business Insights™, the vaccine market is expected to reach USD 104.87 billion by 2027, exhibiting a healthy CAGR of 10.7% during the forecast period, 2020-2027.Pentacel (for Diphtheria, Tetanus, Pertussis, Polio, and Influenza B) by Sanofi that generated USD 2.2 billion in 2019.Shingrix Shingles by GlaxoSmithKline that generated USD 2.3 billion in 2019.Gardasil HPV (Human Papillomavirus) by Merck that generated USD 3.7 billion in 2019.Prevnar-13 Pneumococcal Conjugate by Pfizer that generated USD 5.95 billion in 2019.In terms of revenue, the five leading vaccine products in 2019 were: The market is well-developed in North America and Europe due to the large and robust presence of pharmaceutical bigwigs in these continents and efficient procurement of vaccines by non-governmental organizations such as the Bill and Melinda Gates Foundation and the public-private global health alliance GAVI. GlaxoSmithKline, Merck, Pfizer, and Sanofi currently dominate the market share, controlling around 65%-70% of the market. Today, vaccine formulation, production, and distribution are massive commercial exercises undertaken by giant pharmaceutical companies, giving the global vaccines market a highly consolidated structure. ![]() Vaccines have saved humanity from a wide variety of diseases since their inception in the 1790s in the UK.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |